NDA 020676 · Combe
Vagistat-1
Tioconazole · Vaginal
Last checked: Nov 19, 2026Latest source record: Apr 21, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1997
Feb 11, 1997
Approved uses
1
Original approval plus efficacy supplements
Registered trials
3
1 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 11, 1997 Original approval · Type 8 - Partial Rx to OTC Switch Review
1 products under this application
- VAGISTAT-1 · TIOCONAZOLE 6.5% · OINTMENT, VAGINAL · Over-the-counter
Clinical trials
Interventional ClinicalTrials.gov studies with "Tioconazole" as an intervention, any sponsor and status, largest first.
- Evaluation of Efficacy and Safety of Two New Formulations Compared to Gynomax® XL OvulePivotal-lookingCompleted
Ege UniversityAcademic, hospital or other
NCT06056947 · 577 participants · Start Jul 20, 2020 · Primary completion May 6, 2021
Drug: EVEGYN A; EVEGYN B and 1 more · For: Trichomonal Vaginitis; Bacterial Vaginosis; Candidal Vulvovaginitis and 1 more
Sites: Izmir, Turkey (Türkiye)
Exeltis TurkeyIndustry
NCT03839875 · 116 participants · Start Apr 3, 2019 · Primary completion Aug 9, 2019
Drug: Gynomax® XL Vaginal Ovule · For: Trichomonal Vaginitis; Bacterial Vaginosis; Candidal Vulvovaginitis and 1 more
Sites: Izmir, Turkey (Türkiye)
Cairo UniversityAcademic, hospital or other
NCT05999474 · 30 participants (planned) · Start Sep 1, 2022 · Primary completion Sep 1, 2023
Drug: Topical tioconazole · For: Onychomycosis of Fingernail
Sites: Cairo, Egypt
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Athlete's foot.
Crawford F · BMJ Clin Evid 2009 · Systematic Review
- Fungal toenail infections.
Ferrari J · BMJ Clin Evid 2014 · Systematic Review
- Fungal toenail infections.
Ferrari J · BMJ Clin Evid 2008 · Systematic Review
- Fungal toenail infections.
Ferrari J · BMJ Clin Evid 2011 · Systematic Review
- Combined fractional CO2 laser with topical tioconazole versus Q-switched Nd-YAG laser in the treatment of onychomycosis; a randomized comparative trial.
Sayed K, Khaled M, Gad A, et al. · Lasers Med Sci 2024 · Randomized Controlled Trial, Comparative Study
- Single-dose tioconazole compared with 3-day clotrimazole treatment in vulvovaginal candidiasis.
Stein GE, Gurwith D, Mummaw N, et al. · Antimicrob Agents Chemother 1986 · Clinical Trial, Comparative Study
Sponsor: Combe
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.